-
Article
Open AccessDiscovery of SARS-CoV-2 antiviral synergy between remdesivir and approved drugs in human lung cells
SARS coronavirus 2 (SARS-CoV-2) has caused an ongoing global pandemic with significant mortality and morbidity. At this time, the only FDA-approved therapeutic for COVID-19 is remdesivir, a broad-spectrum anti...
-
Article
Open AccessCombination of antiviral drugs inhibits SARS-CoV-2 polymerase and exonuclease and demonstrates COVID-19 therapeutic potential in viral cell culture
SARS-CoV-2 has an exonuclease-based proofreader, which removes nucleotide inhibitors such as Remdesivir that are incorporated into the viral RNA during replication, reducing the efficacy of these drugs for tre...
-
Article
Open AccessSofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir
SARS-CoV-2 is responsible for COVID-19, resulting in the largest pandemic in over a hundred years. After examining the molecular structures and activities of hepatitis C viral inhibitors and comparing hepatiti...
-
Article
Open AccessPEG-Labeled Nucleotides and Nanopore Detection for Single Molecule DNASequencing by Synthesis
We describe a novel single molecule nanopore-based sequencing by synthesis (Nano-SBS)strategy that can accurately distinguish four bases by detecting 4 different sized tagsreleased from 5?-phosphate-modified n...
